Armando Martins - PROFARMA Director

  Director
Mr. Armando Sereno Diogenes Martins has served as a Member of the Board of Directors of Profarma Distribuidora de Produtos Farmaceuticos SA since April 3, 2008. From 1989 to 1991, he was Financial Consultant at Accenture in the financial institutions sector. He was also Business Development Officer for Grupo Arbi. From 1994 to 1998, he was Senior Officer of Banco de Investimentos Garantia. He was Officer at Credit Suisse First Boston CSFB in Brazil for five years. He founded Singular Assessoria Financeira Ltda in 2003. He gained a degree from New York University and a Bachelor in Telecommunications Engineering from Instituto Militar de Engenharia .
Age: 42  Director Since 2008      
55 21 4009 0200  http://www.profarma.com.br

PROFARMA Management Efficiency

PROFARMA ON NM has return on total asset (ROA) of 1.85 % which means that it generated profit of $1.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.26) %, meaning that it generated substantial loss on money invested by shareholders. PROFARMA management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 900.45 M in total debt with debt to equity ratio (D/E) of 91.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PROFARMA ON NM has a current ratio of 1.24, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist PROFARMA until it has trouble settling it off, either with new capital or with free cash flow. So, PROFARMA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PROFARMA ON NM sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PROFARMA to invest in growth at high rates of return. When we think about PROFARMA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

William ShanahanVISA INC DRN
2007
Tom MurphyBERKSHIRE DRN
2003
Howard BuffettBERKSHIRE DRN
1993
Mary CranstonVISA INC DRN
2007
Thomas MurphyBERKSHIRE DRN
2003
Cathy MinehanVISA INC DRN
2007
Susan DeckerBERKSHIRE DRN
2007
Lloyd CarneyVISA INC DRN
2015
William GatesBERKSHIRE DRN
2005
Suzanne JohnsonVISA INC DRN
2007
Maynard WebbVISA INC DRN
2014
Alfred KellyVISA INC DRN
2019
David GottesmanBERKSHIRE DRN
2003
John SwainsonVISA INC DRN
2013
Stephen BurkeBERKSHIRE DRN
2009
Walter ScottBERKSHIRE DRN
1988
Denise MorrisonVISA INC DRN
2018
Ronald OlsonBERKSHIRE DRN
1997
David PangVISA INC DRN
2007
Meryl WitmerBERKSHIRE DRN
2013
Gary HoffmanVISA INC DRN
2016
Profarma Distrib Prod Farmaceuticos S.A., together with its subsidiaries, engages in the distribution and retail sale of pharmaceutical and hospital products in Brazil. The company was founded in 1961 and is headquartered in Rio de Janeiro, Brazil. PROFARMA operates under Medical Distribution classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 6327 people. PROFARMA ON NM (PFRM3) is traded on Sao Paolo Stock Exchange in Brazil and employs 6,327 people.

PROFARMA ON NM Leadership Team

Elected by the shareholders, the PROFARMA's board of directors comprises two types of representatives: PROFARMA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PROFARMA. The board's role is to monitor PROFARMA's management team and ensure that shareholders' interests are well served. PROFARMA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PROFARMA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sammy Birmarcker, CEO, Member of the Executive Board, Chairman of the Board
Armando Martins, Director
Fernando Perrone, Independent Director
Maximiliano Fischer, CFO, Director of Investor Relations, Member of the Executive Board
Dan Ioschpe, Independent Director
Manoel Birmarcker, Vice Chairman of the Board

PROFARMA Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PROFARMA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

PROFARMA Investors Sentiment

The influence of PROFARMA's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in PROFARMA. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PROFARMA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PROFARMA's short interest history, or implied volatility extrapolated from PROFARMA options trading.

Currently Active Assets on Macroaxis

Check out Your Equity Center. Note that the PROFARMA ON NM information on this page should be used as a complementary analysis to other PROFARMA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Tools for PROFARMA Stock

When running PROFARMA ON NM price analysis, check to measure PROFARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PROFARMA is operating at the current time. Most of PROFARMA's value examination focuses on studying past and present price action to predict the probability of PROFARMA's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move PROFARMA's price. Additionally, you may evaluate how the addition of PROFARMA to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go